The aim of this study was to assess the prognostic value of normal ultra-low-dose exercise MPI with a CZT camera. METHODS: 1901 consecutive patients without known CAD referred for exercise MPI with 1.8 MBq/kg (0.05 mCi) of Tc99m sestamibi or tetrofosmin and a CZT camera were included prospectively. Patients with an abnormal scan requiring an additional resting image (230) or a submaximal exercise test (271) were excluded. The 1400 remaining patients were followed for 39 months. The primary end-point was cardiac events (cardiac death, nonfatal myocardial infarction, and revascularization). The secondary end-point was noncardiac death. RESULTS: The mean injected activity was 145 ± 37 MBq (3.9 ± 1 mCi), the mean acquisition duration was 10 ± 0.7 minutes, and the mean effective dose was 0.91 ± 0.13 mSv. 1288 patients (92%) achieved full follow-up. We observed 22 cardiac events and 16 noncardiac deaths. The annualized rates were equivalent to 0.55% for cardiac events and 0.37% for noncardiac mortality. CONCLUSIONS: Normal ultra-low-dose exercise MPI with a CZT camera has a high negative predictive value. The effective dose was less than 1 mSv, and the study thus allays concerns about radiation burden.
The aim of this study was to assess the prognostic value of normal ultra-low-dose exercise MPI with a CZT camera. METHODS: 1901 consecutive patients without known CAD referred for exercise MPI with 1.8 MBq/kg (0.05 mCi) of Tc99m sestamibi or tetrofosmin and a CZT camera were included prospectively. Patients with an abnormal scan requiring an additional resting image (230) or a submaximal exercise test (271) were excluded. The 1400 remaining patients were followed for 39 months. The primary end-point was cardiac events (cardiac death, nonfatal myocardial infarction, and revascularization). The secondary end-point was noncardiac death. RESULTS: The mean injected activity was 145 ± 37 MBq (3.9 ± 1 mCi), the mean acquisition duration was 10 ± 0.7 minutes, and the mean effective dose was 0.91 ± 0.13 mSv. 1288 patients (92%) achieved full follow-up. We observed 22 cardiac events and 16 noncardiac deaths. The annualized rates were equivalent to 0.55% for cardiac events and 0.37% for noncardiac mortality. CONCLUSIONS: Normal ultra-low-dose exercise MPI with a CZT camera has a high negative predictive value. The effective dose was less than 1 mSv, and the study thus allays concerns about radiation burden.
Authors: W Lane Duvall; Joseph M Sweeny; Lori B Croft; Maya H Barghash; Nitin K Kulkarni; Krista A Guma; Milena J Henzlova Journal: J Nucl Cardiol Date: 2011-06-03 Impact factor: 5.952
Authors: Andrew J Einstein; Lynne L Johnson; Albert J DeLuca; Andrew C Kontak; Daniel W Groves; Jennifer Stant; Ted Pozniakoff; Bin Cheng; LeRoy E Rabbani; Sabahat Bokhari Journal: J Nucl Med Date: 2015-03-05 Impact factor: 10.057
Authors: Michael Fiechter; Jelena R Ghadri; Silke M Kuest; Aju P Pazhenkottil; Mathias Wolfrum; Rene N Nkoulou; Robert Goetti; Oliver Gaemperli; Philipp A Kaufmann Journal: Eur J Nucl Med Mol Imaging Date: 2011-07-15 Impact factor: 9.236
Authors: R Hachamovitch; D S Berman; L J Shaw; H Kiat; I Cohen; J A Cabico; J Friedman; G A Diamond Journal: Circulation Date: 1998-02-17 Impact factor: 29.690
Authors: Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden Journal: Circulation Date: 2008-02-11 Impact factor: 29.690
Authors: Marvin Grossmann; Andreas A Giannopoulos; Fabiola A Bechtiger; Michael Messerli; Moritz Schwyzer; Dominik C Benz; Ken Kudura; Catherine Gebhard; Christoph Gräni; Aju P Pazhenkottil; Philipp A Kaufmann; Ronny R Buechel Journal: J Nucl Cardiol Date: 2018-06-19 Impact factor: 5.952
Authors: Firas J Al Badarin; John A Spertus; Timothy M Bateman; Krishna K Patel; Eric V Burgett; Kevin F Kennedy; Randall C Thompson Journal: J Nucl Cardiol Date: 2019-01-31 Impact factor: 5.952